Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Sep 15;98(6):1423–1431. doi: 10.1172/JCI118930

A novel missense mutation in the amino-terminal domain of the human androgen receptor gene in a family with partial androgen insensitivity syndrome causes reduced efficiency of protein translation.

C S Choong 1, C A Quigley 1, F S French 1, E M Wilson 1
PMCID: PMC507569  PMID: 8823308

Abstract

The role of the androgen receptor (AR) in male sexual differentiation is revealed in part by the analysis of naturally occurring mutations in families with androgen insensitivity syndrome (AIS). We have investigated a family with partial AIS affecting three generations and have identified a G to A substitution in the AR gene at the fourth position 3' from the A of the ATG initiation codon changing the second amino acid residue from glutamic acid to lysine (EK2). Transient expression of the mutant EK2-pCMVhAR expression vector in COS cells revealed decreased translation with a 20-50% reduction in mutant protein relative to wild type AR by immunoblot analysis. The rate of dissociation of [3H]methyltrienolone from the EK2 mutant (half-time [t1/2] = 1.7 +/- 0.08 SE h) was increased compared with wild type AR (t1/2 = 2.4 +/- 0.11 h). Cotransfection studies using an androgen responsive luciferase reporter vector demonstrated a 50% reduction in transcriptional activation by EK2. These functional alterations are consistent with the partial AIS phenotype in affected males, corroborate the AR amino-terminal domain effect on kinetics of androgen binding, and provide physiological evidence for earlier translation experiments identifying the nucleotide sequence for optimal translation initiation.

Full Text

The Full Text of this article is available as a PDF (336.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson S., Davis D. L., Dahlbäck H., Jörnvall H., Russell D. W. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem. 1989 May 15;264(14):8222–8229. [PubMed] [Google Scholar]
  2. Batch J. A., Williams D. M., Davies H. R., Brown B. D., Evans B. A., Hughes I. A., Patterson M. N. Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome. Hum Mol Genet. 1992 Oct;1(7):497–503. doi: 10.1093/hmg/1.7.497. [DOI] [PubMed] [Google Scholar]
  3. Brinkmann A. O., Jenster G., Ris-Stalpers C., van der Korput J. A., Brüggenwirth H. T., Boehmer A. L., Trapman J. Androgen receptor mutations. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):443–448. doi: 10.1016/0960-0760(95)00090-m. [DOI] [PubMed] [Google Scholar]
  4. Brown T. R. Human androgen insensitivity syndrome. J Androl. 1995 Jul-Aug;16(4):299–303. [PubMed] [Google Scholar]
  5. Chang C. S., Kokontis J., Liao S. T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science. 1988 Apr 15;240(4850):324–326. doi: 10.1126/science.3353726. [DOI] [PubMed] [Google Scholar]
  6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  7. Choong C. S., Sturm M. J., Strophair J. A., McCulloch R. K., Tilley W. D., Leedman P. J., Hurley D. M. Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly-->Arg) that results in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels. J Clin Endocrinol Metab. 1996 Jan;81(1):236–243. doi: 10.1210/jcem.81.1.8550758. [DOI] [PubMed] [Google Scholar]
  8. De Bellis A., Quigley C. A., Cariello N. F., el-Awady M. K., Sar M., Lane M. V., Wilson E. M., French F. S. Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modified denaturing gradient gel electrophoresis technique. Mol Endocrinol. 1992 Nov;6(11):1909–1920. doi: 10.1210/mend.6.11.1480178. [DOI] [PubMed] [Google Scholar]
  9. De Bellis A., Quigley C. A., Marschke K. B., el-Awady M. K., Lane M. V., Smith E. P., Sar M., Wilson E. M., French F. S. Characterization of mutant androgen receptors causing partial androgen insensitivity syndrome. J Clin Endocrinol Metab. 1994 Mar;78(3):513–522. doi: 10.1210/jcem.78.3.8126121. [DOI] [PubMed] [Google Scholar]
  10. Hiort O., Wodtke A., Struve D., Zöllner A., Sinnecker G. H. Detection of point mutations in the androgen receptor gene using non-isotopic single strand conformation polymorphism analysis. German Collaborative Intersex Study Group. Hum Mol Genet. 1994 Jul;3(7):1163–1166. doi: 10.1093/hmg/3.7.1163. [DOI] [PubMed] [Google Scholar]
  11. Kelce W. R., Stone C. R., Laws S. C., Gray L. E., Kemppainen J. A., Wilson E. M. Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature. 1995 Jun 15;375(6532):581–585. doi: 10.1038/375581a0. [DOI] [PubMed] [Google Scholar]
  12. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987 Oct 26;15(20):8125–8148. doi: 10.1093/nar/15.20.8125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell. 1986 Jan 31;44(2):283–292. doi: 10.1016/0092-8674(86)90762-2. [DOI] [PubMed] [Google Scholar]
  14. Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem. 1991 Oct 25;266(30):19867–19870. [PubMed] [Google Scholar]
  15. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  16. La Spada A. R., Wilson E. M., Lubahn D. B., Harding A. E., Fischbeck K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991 Jul 4;352(6330):77–79. doi: 10.1038/352077a0. [DOI] [PubMed] [Google Scholar]
  17. Langley E., Zhou Z. X., Wilson E. M. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem. 1995 Dec 15;270(50):29983–29990. doi: 10.1074/jbc.270.50.29983. [DOI] [PubMed] [Google Scholar]
  18. Lubahn D. B., Joseph D. R., Sar M., Tan J., Higgs H. N., Larson R. E., French F. S., Wilson E. M. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol. 1988 Dec;2(12):1265–1275. doi: 10.1210/mend-2-12-1265. [DOI] [PubMed] [Google Scholar]
  19. Lubahn D. B., Joseph D. R., Sar M., Tan J., Higgs H. N., Larson R. E., French F. S., Wilson E. M. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol. 1988 Dec;2(12):1265–1275. doi: 10.1210/mend-2-12-1265. [DOI] [PubMed] [Google Scholar]
  20. Lubahn D. B., Joseph D. R., Sullivan P. M., Willard H. F., French F. S., Wilson E. M. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science. 1988 Apr 15;240(4850):327–330. doi: 10.1126/science.3353727. [DOI] [PubMed] [Google Scholar]
  21. McPhaul M. J., Marcelli M., Zoppi S., Griffin J. E., Wilson J. D. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance. J Clin Endocrinol Metab. 1993 Jan;76(1):17–23. doi: 10.1210/jcem.76.1.8421085. [DOI] [PubMed] [Google Scholar]
  22. Morlé F., Lopez B., Henni T., Godet J. alpha-Thalassaemia associated with the deletion of two nucleotides at position -2 and -3 preceding the AUG codon. EMBO J. 1985 May;4(5):1245–1250. doi: 10.1002/j.1460-2075.1985.tb03767.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pinsky L., Trifiro M., Kaufman M., Beitel L. K., Mhatre A., Kazemi-Esfarjani P., Sabbaghian N., Lumbroso R., Alvarado C., Vasiliou M. Androgen resistance due to mutation of the androgen receptor. Clin Invest Med. 1992 Oct;15(5):456–472. [PubMed] [Google Scholar]
  24. Quarmby V. E., Yarbrough W. G., Lubahn D. B., French F. S., Wilson E. M. Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol. 1990 Jan;4(1):22–28. doi: 10.1210/mend-4-1-22. [DOI] [PubMed] [Google Scholar]
  25. Quigley C. A., De Bellis A., Marschke K. B., el-Awady M. K., Wilson E. M., French F. S. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995 Jun;16(3):271–321. doi: 10.1210/edrv-16-3-271. [DOI] [PubMed] [Google Scholar]
  26. Simental J. A., Sar M., Lane M. V., French F. S., Wilson E. M. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem. 1991 Jan 5;266(1):510–518. [PubMed] [Google Scholar]
  27. Wong C. I., Zhou Z. X., Sar M., Wilson E. M. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem. 1993 Sep 5;268(25):19004–19012. [PubMed] [Google Scholar]
  28. Zhou Z. X., Lane M. V., Kemppainen J. A., French F. S., Wilson E. M. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol. 1995 Feb;9(2):208–218. doi: 10.1210/mend.9.2.7776971. [DOI] [PubMed] [Google Scholar]
  29. Zhou Z. X., Wong C. I., Sar M., Wilson E. M. The androgen receptor: an overview. Recent Prog Horm Res. 1994;49:249–274. doi: 10.1016/b978-0-12-571149-4.50017-9. [DOI] [PubMed] [Google Scholar]
  30. Zoppi S., Wilson C. M., Harbison M. D., Griffin J. E., Wilson J. D., McPhaul M. J., Marcelli M. Complete testicular feminization caused by an amino-terminal truncation of the androgen receptor with downstream initiation. J Clin Invest. 1993 Mar;91(3):1105–1112. doi: 10.1172/JCI116269. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES